Bottom line
All currently approved GLP-1 medications carry FDA labeling recommending discontinuation before pregnancy. The specific guidance:
- Semaglutide (Ozempic, Wegovy, Rybelsus, Wegovy pill):
discontinue at least 2 months before a planned pregnancy.
- Tirzepatide (Mounjaro, Zepbound): discontinue at least
2 months before a planned pregnancy (consistent with the ~5-week clearance time plus a safety margin).
- Liraglutide (Saxenda, Victoza): discontinue at least
2 months before, despite the shorter half-life, per labeling.
These recommendations are based on animal reproductive toxicity data (fetal harm observed in animal studies at clinically relevant exposures) and the absence of adequate human data. There are no controlled trials of GLP-1s in pregnant humans and there likely never will be — the ethical constraints are obvious.
At the same time, weight loss itself can meaningfully improve fertility in patients with obesity-related reproductive dysfunction. This creates a clinical paradox: the drug that improves fertility is the drug you have to stop before using that fertility. Managing this transition is the core clinical challenge.
How GLP-1s can improve fertility
Obesity is independently associated with reduced fertility in both women and men through multiple mechanisms:
In women:
- Insulin resistance drives excess androgen production in the
ovaries, contributing to anovulation (the hallmark of PCOS)
- Excess adipose tissue aromatizes androgens to estrogens,
disrupting the hypothalamic-pituitary-ovarian axis
- Higher BMI is associated with lower success rates in assisted
reproduction (IVF/IUI)
- Obesity increases miscarriage risk
In men:
- Obesity is associated with lower testosterone, higher
estradiol, and reduced sperm quality
- Insulin resistance independently impairs spermatogenesis
Weight loss of 5-10% can restore ovulatory cycles in many women with PCOS-related anovulation. The STEP trials and SURMOUNT trials showed that GLP-1s produce far more than 5-10% weight loss in most patients — and clinical reports of "Ozempic babies" (unplanned pregnancies during GLP-1 treatment) have become frequent enough to warrant attention.
The mechanism appears to be straightforward: meaningful weight loss restores hormonal balance, ovulatory function returns (sometimes rapidly), and patients who have been unable to conceive for years become fertile — sometimes before they realize it.
The "Ozempic babies" phenomenon
The popular term refers to unplanned pregnancies occurring in patients taking GLP-1 medications, often in patients who had been told they were unlikely to conceive naturally. The phenomenon is real and well-documented anecdotally, though formal epidemiological data are still accumulating.
Key points:
- GLP-1s are not fertility drugs. They do not directly
stimulate ovulation. The fertility improvement is an indirect effect of weight loss and metabolic normalization.
- GLP-1s may reduce the effectiveness of oral contraceptives.
The delayed gastric emptying caused by GLP-1s can slow absorption of oral medications, potentially reducing contraceptive efficacy. The Wegovy labeling specifically notes this interaction and recommends barrier methods or switching to a non-oral contraceptive.
- The pregnancies are occurring during the weight-loss phase
of treatment, when patients are still taking the drug — which is exactly when the FDA says to discontinue.
- There is no signal of increased birth defect rates in the
limited human data available from inadvertent exposures, but the data are insufficient to establish safety.
If you're planning a pregnancy
The recommended clinical approach in 2026:
Phase 1: Lose weight on the GLP-1 (3-12+ months). If fertility is a future goal but not immediate, GLP-1 therapy can be an excellent tool for reaching a healthier BMI before conception. A BMI reduction into the 25-30 range meaningfully improves pregnancy outcomes — lower rates of gestational diabetes, preeclampsia, cesarean delivery, and macrosomia.
During this phase, use reliable contraception. Given the oral contraceptive absorption concern, your prescriber may recommend a non-oral method (IUD, implant, injectable, or barrier).
Phase 2: Discontinue the GLP-1 (≥2 months before conception attempts). The 2-month window allows full drug clearance plus a buffer. Semaglutide's half-life is ~7 days, so 5 half-lives (full clearance) is ~5 weeks. Tirzepatide's half-life is ~5 days, so full clearance is ~25 days. The 2-month recommendation provides additional margin.
During this window:
- Expect some return of appetite. Lean into the protein and
behavioral strategies from our discontinuation guide
- Start prenatal vitamins (folic acid ≥400 mcg/day minimum)
if you haven't already
- Track ovulation if desired — cycles may be irregular
initially as hormones recalibrate
Phase 3: Conception, pregnancy, and postpartum. GLP-1s are not resumed during pregnancy or breastfeeding. The animal data showing fetal harm make this a clear boundary. If weight management is a concern postpartum, the discussion about restarting can happen after breastfeeding concludes (or earlier if not breastfeeding, per prescriber guidance).
What if you get pregnant while on a GLP-1?
This happens, and it is not a cause for panic:
- Stop the medication immediately and contact your
prescriber and OB-GYN.
- The drug will clear your system within 5-7 weeks depending
on the molecule.
- Current case-series data from inadvertent exposures do not
show a clear pattern of birth defects, though the data are limited and cannot establish safety.
- Your OB-GYN will likely recommend standard monitoring
(anatomy scan, growth scans) and may refer you to a maternal-fetal medicine specialist depending on the timing and duration of exposure.
- Do not restart the GLP-1 during the remainder of the
pregnancy.
The situation is analogous to many other medications that are discontinued upon discovery of pregnancy. The key is prompt discontinuation and appropriate monitoring.
GLP-1s and male fertility
The evidence here is thinner but generally positive:
- Weight loss in obese men is associated with improved
testosterone levels and sperm parameters.
- Animal studies of GLP-1 agonists have shown mixed results on
male reproductive organs, with some showing testicular effects at high doses.
- The FDA labeling for semaglutide and tirzepatide does not
include specific male fertility recommendations, but many reproductive endocrinologists recommend the same 2-month washout for men planning to conceive, as a precautionary measure.
If male fertility is a concern, a semen analysis before and during GLP-1 treatment can provide objective data.
What to ask your prescriber
If fertility is part of your picture:
- "What's the timeline — how long should I be on the GLP-1
before we plan the transition off?"
- "What contraception do you recommend while I'm on the drug?"
- "Should I switch from oral contraceptives to something else
given the absorption issue?"
- "What's the exact washout timing for my specific drug?"
- "Can you coordinate with my OB-GYN or reproductive
endocrinologist on the transition plan?"
- "If I get pregnant while on the drug, what monitoring do
you recommend?"
What this means for you
GLP-1 therapy and fertility planning are not incompatible — they just require sequencing. The drug can dramatically improve your metabolic and reproductive health through weight loss. The drug then needs to be stopped before you attempt conception.
The patients who navigate this best are the ones who tell their prescriber about their fertility goals from the beginning, so the treatment plan accounts for the transition. The worst outcomes happen when patients don't mention fertility goals, get pregnant on the drug, and panic. Early communication prevents that.